Search Results 101-110 of 21221 for Inhibition

1. Transcript of sound bite comments on new class of PCSK9 inhibitor cholesterol lowering medications awaiting FDA approval. Steph

   Transcript of sound bite comments on new class of PCSK9 inhibitor cholesterol lowering medications awaiting FDA approval. Stephen Kopecky, M.D. / Mayo ...

2. Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer

   A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) ...

3. Slowing or reversing muscle loss - Mayo Clinic

   These observations have led to the hypothesis that myostatin inhibition could serve as a means to attenuate or reverse skeletal muscle mass loss in patients ...

4. Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma - Mayo Clinic

   PI3K-delta inhibitor TGR-1202 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as ...

5. Risk Prediction for Immune Checkpoint Inhibitor Associated Diabetes Mellitus - Mayo Clinic

   Risk Prediction for Immune Checkpoint Inhibitor Associated Diabetes Mellitus · Overview · Participation eligibility · Participating Mayo Clinic locations · More ...

6. Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis - Mayo Clinic

   Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis · Overview · Participation eligibility · Participating Mayo Clinic ...

7. Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination with Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer - Mayo Clinic

   Dabrafenib is a potent and selective inhibitor of BRAF kinase activity. This is a Phase II, non-randomized, open-label study to assess the efficacy, safety, and ...

8. Translational Neuro-Oncology: Jann N. Sarkaria - Research Projects

   Research in the Sarkaria Translational Neuro-Oncology Lab at Mayo Clinic focuses on ADC biology, MDM2 inhibitors, DNA damage response inhibitors and ...

9. Guidance Needed on PDL1-Inhibitors - Mayo Clinic News Network

   These antibodies work the same way in cancer, to prevent cancer cells from turning off immune cell production. PDL1 Inhibitors: Unmasking Cancer Cells have ...

10. Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301) - Mayo Clinic

    The study is designed as a three arm randomized Phase III, multicenter trial comparing two calcineurin inhibitor (CNI)-free strategies for Graft-versus-Host ...